


OPEN

# Author Correction: Amine oxidase 3 is a novel pro-inflammatory marker of oxidative stress in peritoneal endometriosis lesions

Published online: 24 March 2020

Marie-Laëtitia Thézénas, Bianca De Leo, Alexis Laux-Biehlmann, Cemsal Bafligil , Bernd Elger, Thomas Tapmeier , Karl Morten, Nilufer Rahmioglu, Stephanie G. Dakin, Philip Charles , Fernando Estrada Martinez, Graham Steers, Oliver M. Fischer, Joerg Mueller, Holger Hess-Stumpp, Andreas Steinmeyer, Sanjiv Manek, Krina T. Zondervan , Stephen Kennedy, Christian M. Becker , Catherine Shang, Thomas M. Zollner, Benedikt M. Kessler  & Udo Oppermann 

Correction to: *Scientific Reports* <https://doi.org/10.1038/s41598-020-58362-3>, published online 30 January 2020

In Figure 5A, the chemical structure is incorrect. As a result, the Figure legend,

“AOC3 inhibitor PXS-4681A shows analgesic effects in the endometriosis inoculation mouse model.


(A) Structure of AOC3 inhibitor PXS-4681A, orally administered BID at 2 mg/kg. (B) Unbound plasma levels of PXS-4681A (at 1-2-4 mg/kg). (C) Target engagement results (2 mg/kg). (D) Changes in H<sub>2</sub>O<sub>2</sub> in plasma. (E) Plasma exposure of PXS-4681A at day 2. (F) Front/rear paw ratio measure using the dynamic weight bearing system indicating reduction of pain behaviour under treatment.”

should read:

“AOC3 inhibitor PXS-4681A shows analgesic effects in the endometriosis inoculation mouse model.

(A) Structure of AOC3 inhibitor PXS-4681A, orally administered BID at 2 mg/kg. The compound was synthesized according to literature procedures<sup>37</sup> (B) Unbound plasma levels of PXS-4681A (at 1-2-4 mg/kg). (C) Target engagement results (2 mg/kg). (D) Changes in H<sub>2</sub>O<sub>2</sub> in plasma. (E) Plasma exposure of PXS-4681A at day 2. (F) Front/rear paw ratio measure using the dynamic weight bearing system indicating reduction of pain behaviour under treatment.”

The correct Figure 5 and its accompanying legend appear below as Figure 1.



**Figure 1.** AOC3 inhibitor PXS-4681A shows analgesic effects in the endometriosis inoculation mouse model. **(A)** Structure of AOC3 inhibitor PXS-4681A, orally administered BID at 2 mg/kg. The compound was synthesized according to literature procedures<sup>37</sup> **(B)** Unbound plasma levels of PXS-4681A (at 1-2-4 mg/kg). **(C)** Target engagement results (2 mg/kg). **(D)** Changes in H<sub>2</sub>O<sub>2</sub> in plasma. **(E)** Plasma exposure of PXS-4681A at day 2. **(F)** Front/rear paw ratio measure using the dynamic weight bearing system indicating reduction of pain behaviour under treatment.



**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2020